Program
rotigotine
Also written as “Rotigotine”, “SPM 962” and “Rotigotine transdermal patch”.
Its studies are mostly in Parkinson Disease · Restless Legs Syndrome · Fibromyalgia, led by 5 companies.
Drug pageRotigotine: every studyMany companies study it; this page follows only the 63 they lead. All 77 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| UCBits history only | 500 open or running | phase 4since Dec 21, 2007 | Aug 24, 2005 | none ahead |
| Otsukaits history only | 100 open or running | phase 3since Sep 27, 2007 | Sep 27, 2007 | none ahead |
| Eva Pharmaits history only | 11 open or running | no phasesince May 30, 2025 | May 30, 2025 | none ahead |
| Inflamax Researchits history only | 10 open or running | phase 1since Feb 25, 2016 | Feb 25, 2016 | none ahead |
| Luye Pharma Groupits history only | 10 open or running | phase 1since Mar 31, 2016 | Mar 31, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Oct 24, 2005.
- Aug 27, 2012Phase 1 study in HealthyUCB · NCT01675024 · 24 enrolled · China
- Oct 18, 2012Phase 4 study in Advanced Idiopathic Parkinson's DiseaseUCB · NCT01711866 · 87 enrolled · United States, Korea, Republic of, Malaysia and more
- Nov 6, 2012Phase 3 study in Advanced Parkinson's DiseaseUCB · NCT01723904 · 90 enrolled · Australia, Korea, Republic of, Malaysia and more
- Dec 5, 2012Phase 4 study in Parkinson DiseaseUCB · NCT01744496 · 68 enrolled · United States, Germany, Poland and more
- Jan 3, 2013Phase 1 study in HealthyUCB · NCT01761526 · 50 enrolled · Germany
- Jan 30, 2013Phase 4 study in Parkinson DiseaseUCB · NCT01782222 · 122 enrolled · United States, Austria, Hungary and more
- May 10, 2013Phase 1 study in HealthyUCB · NCT01854216 · 26 enrolled · Germany
- Oct 14, 2013Phase 1 study in Parkinson DiseaseUCB · NCT01964573 · 48 enrolled · Korea, Republic of
- Aug 29, 2014Phase 1 study in Parkinson DiseaseUCB · NCT02230904 · 57 enrolled · Germany
- Feb 25, 2016Inflamax Research’s first study: phase 1 study in Bioequivalence - Irritation and Sensitization Potential of Transdermal PatchNew to Inflamax ResearchInflamax Research · NCT02727205 · 260 enrolled · United States, Canada
- Mar 31, 2016Luye Pharma Group’s first study: phase 1 study in Parkinson DiseaseNew to Luye Pharma GroupLuye Pharma Group · NCT02728947 · 28 enrolled · United States
- Oct 31, 2018Phase 3 study in Restless Legs SyndromeUCB · NCT03728933 · 23 enrolled · United States
- Jun 17, 2019Phase 3 study in Restless Legs SyndromeUCB · NCT03992196 · 10 enrolled · United States
- May 30, 2025Eva Pharma’s first study: no phase study in Parkinson DiseaseNew to Eva PharmaEva Pharma · NCT07015346 · 40 planned
TargetBeta
“D2-like dopamine receptor agonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| Pramipexolerule | Boehringer Ingelheim | phase 4 | 44 |
Studies
The newest 60 of 63 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07015346Parkinson Disease | – | Not yet recruiting | Eva Pharma | Oct 15, 2025 | 40 |
| NCT03992196Restless Legs Syndrome · United States | 3 | Terminated | UCB | Sep 1, 2022 | 10 |
| NCT03728933Restless Legs Syndrome · United States | 3 | Terminated | UCB | Jul 25, 2022 | 23 |
| NCT02728947Parkinson Disease · United States | 1 | Completed | Luye Pharma Group | Aug 2016 | 28 |
| NCT02727205Bioequivalence - Irritation and Sensitization Potential of Transdermal Patch · United States, Canada | 1 | Completed | Inflamax Research | Oct 2013 | 260 |
| NCT02230904Parkinson Disease · Germany | 1 | Completed | UCB | Nov 2014 | 57 |
| NCT01964573Parkinson Disease · Korea, Republic of | 1 | Completed | UCB | Feb 2007 | 48 |
| NCT01854216Healthy · Germany | 1 | Completed | UCB | Mar 2003 | 26 |
| NCT01782222Parkinson Disease · United States, Austria, Hungary and more | 4 | Completed | UCB | Jan 2014 | 122 |
| NCT01761526Healthy · Germany | 1 | Completed | UCB | Oct 2002 | 50 |
| NCT01744496Parkinson Disease · United States, Germany, Poland and more | 4 | Completed | UCB | Dec 2013 | 68 |
| NCT01723904Advanced Parkinson's Disease · Australia, Korea, Republic of, Malaysia and more | 3 | Completed | UCB | Mar 2013 | 90 |
| NCT01711866Advanced Idiopathic Parkinson's Disease · United States, Korea, Republic of, Malaysia and more | 4 | Completed | UCB | Mar 2013 | 87 |
| NCT01675024Healthy · China | 1 | Completed | UCB | Sep 2012 | 24 |
| NCT01646268Parkinson Disease · China | 3 | Completed | UCB | May 2014 | 249 |
| NCT01646255Parkinson Disease · China | 3 | Completed | UCB | Oct 2014 | 346 |
| NCT01634243Parkinson Disease · Japan | 2 | Completed | Otsuka | May 2006 | 64 |
| NCT01631825Parkinson Disease · Japan | 3 | Completed | Otsuka | Jun 2012 | 321 |
| NCT01631812Parkinson Disease · Japan | 2 | Completed | Otsuka | Feb 2010 | 130 |
| NCT01628965Parkinson Disease · Japan | 3 | Completed | Otsuka | Oct 2010 | 143 |
| NCT01628926Parkinson Disease · Japan | 3 | Completed | Otsuka | May 2011 | 420 |
| NCT01628848Parkinson Disease · Japan | 2 | Completed | Otsuka | Apr 2008 | 174 |
| NCT01569464Restless Legs Syndrome · United States | 3 | Completed | UCB | Apr 2013 | 150 |
| NCT01565018Healthy Volunteers · Germany | 1 | Completed | UCB | Jul 2012 | 55 |
| NCT01562743Idiopathic Restless Legs Syndrome | 2 | Completed | Otsuka | Oct 2010 | 185 |
| NCT01537042Restless Legs Syndrome · United States, Austria, Finland and more | 3 | Completed | UCB | Oct 2013 | 30 |
| NCT01536015Advanced Parkinson's Disease · United States | 3 | Terminated | UCB | Oct 2013 | 25 |
| NCT01523301Parkinson Disease · Korea, Republic of | 4 | Completed | UCB | Oct 2014 | 380 |
| NCT01498120Restless Legs Syndrome · United States | 2 | Completed | UCB | Dec 2015 | 14 |
| NCT01495793Restless Legs Syndrome · United States | 2 | Completed | UCB | May 2014 | 42 |
| NCT01455012Restless Legs Syndrome · Germany | 4 | Completed | UCB | May 2012 | 81 |
| NCT01338896Parkinson Disease · Austria, Germany, United Kingdom | 1 | Completed | UCB | May 2011 | 56 |
| NCT01300819Parkinson Disease · Austria, Belgium, Bulgaria and more | 4 | Completed | UCB | Oct 2012 | 349 |
| NCT01084551Idiopathic Restless Legs Syndrome · Japan | 3 | Completed | Otsuka | Sep 2011 | 284 |
| NCT01059903Healthy Volunteers · Germany | 1 | Completed | UCB | Feb 2010 | 50 |
| NCT00957944Healthy Volunteers · Germany | 1 | Completed | UCB | Aug 2009 | 40 |
| NCT00881894Healthy · Germany | 1 | Completed | UCB | Nov 2008 | 52 |
| NCT00666965Idiopathic Restless Legs Syndrome · Japan | 2 | Completed | Otsuka | Aug 2009 | 230 |
| NCT00599196Early Stage Parkinson's Disease · Australia, Austria, Belgium and more | 3 | Completed | UCB | Dec 2008 | 381 |
| NCT00594386Parkinson Disease · United States, Canada | 3 | Completed | UCB | Dec 2008 | 258 |
| NCT00594165Parkinson Disease · United States, Canada | 3 | Completed | UCB | Nov 2008 | 217 |
| NCT00594464Parkinson Disease · Germany | 4 | Completed | UCB | May 2008 | 14 |
| NCT00593606Parkinson Disease | 3 | Completed | UCB | Dec 2007 | 124 |
| NCT00537485Parkinson Disease · Japan | 3 | Completed | Otsuka | Dec 2009 | 180 |
| NCT00522379Parkinson Disease · United States, Chile, India and more | 3 | Completed | UCB | Jul 2011 | 514 |
| NCT00519532Parkinson Disease · United States, Australia, Finland and more | 3 | Terminated | UCB | May 2009 | 84 |
| NCT00505687Parkinson Disease · United States, Austria, Germany and more | 3 | Completed | UCB | Dec 2008 | 186 |
| NCT00501969Advanced Stage Parkinson's Disease · Australia, Austria, Croatia and more | 3 | Completed | UCB | Dec 2008 | 395 |
| NCT00498186Restless Legs Syndrome · Austria, Germany, Spain | 2 | Completed | UCB | Apr 2009 | 295 |
| NCT00498108Restless Legs Syndrome · Germany | 3 | Completed | UCB | Sep 2007 | 341 |
| NCT00474058Parkinson Disease · United States, Australia, Austria and more | 3 | Completed | UCB | Mar 2009 | 287 |
| NCT00464737Fibromyalgia · United States | 2 | Completed | UCB | Nov 2008 | 230 |
| NCT00389831Restless Legs Syndrome · Germany | 2 | Completed | UCB | Nov 2006 | 44 |
| NCT00296192Parkinson Disease | 2 | Completed | UCB | Jun 2006 | 82 |
| NCT00292227Parkinson Disease · South Africa | 1 | Completed | UCB | Sep 2006 | 130 |
| NCT00275236Restless Legs Syndrome · Germany | 3 | Completed | UCB | Jul 2006 | 60 |
| NCT00263068Restless Legs Syndrome · United States | 3 | Completed | UCB | Dec 2007 | 279 |
| NCT00244387Parkinson Disease · Germany | 3 | Completed | UCB | Jul 2005 | 506 |
| NCT00243971Parkinson Disease · Germany | 3 | Completed | UCB | Oct 2005 | |
| NCT00243945Parkinson Disease · Germany | 3 | Completed | UCB | Jul 2005 | 58 |
How it is read
Names in the registry
- “Rotigotine”, 39 entries
- “SPM 962”, 13 entries
- “Rotigotine transdermal patch”, 4 entries
- “Rotigexole 8 mg”, 1 entry
- “Rotigotine 1 mg/24 h”, 1 entry
Conditions, from the studies’ own filings
- Parkinson Disease, 38 studies
- Restless Legs Syndrome, 17 studies
- Fibromyalgia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.